Omnicell Competitors

Cerner (NASDAQ:CERN) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Cerner and Omnicell's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cerner and Omnicell, as reported by MarketBeat.com.

Cerner currently has a consensus price target of $79.7778, indicating a potential upside of 13.72%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Cerner's higher possible upside, equities research analysts plainly believe Cerner is more favorable than Omnicell.

Valuation & Earnings

This table compares Cerner and Omnicell's revenue, earnings per share and valuation.

Cerner has higher revenue and earnings than Omnicell. Cerner is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.0% of Cerner shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 0.3% of Cerner shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Cerner has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Cerner beats Omnicell on 8 of the 14 factors compared between the two stocks.

AmerisourceBergen (NYSE:ABC) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares AmerisourceBergen and Omnicell's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AmerisourceBergen and Omnicell, as reported by MarketBeat.com.

AmerisourceBergen currently has a consensus price target of $121.1111, indicating a potential upside of 17.39%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given AmerisourceBergen's higher possible upside, equities research analysts plainly believe AmerisourceBergen is more favorable than Omnicell.

Valuation & Earnings

This table compares AmerisourceBergen and Omnicell's revenue, earnings per share and valuation.

Omnicell has lower revenue, but higher earnings than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.4% of AmerisourceBergen shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 28.3% of AmerisourceBergen shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

AmerisourceBergen has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Omnicell beats AmerisourceBergen on 8 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider & Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares West Pharmaceutical Services and Omnicell's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares West Pharmaceutical Services and Omnicell's revenue, earnings per share and valuation.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for West Pharmaceutical Services and Omnicell, as reported by MarketBeat.com.

West Pharmaceutical Services currently has a consensus price target of $310.00, indicating a potential upside of 9.54%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given West Pharmaceutical Services' higher possible upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than Omnicell.

Volatility and Risk

West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Omnicell on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by company insiders. Comparatively, 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics Public and Omnicell's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Omnicell's top-line revenue, earnings per share and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Omnicell. Horizon Therapeutics Public is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Horizon Therapeutics Public and Omnicell, as provided by MarketBeat.

Horizon Therapeutics Public presently has a consensus price target of $101.8889, indicating a potential upside of 10.86%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Omnicell.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Omnicell on 11 of the 14 factors compared between the two stocks.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Omnicell's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Fresenius Medical Care AG & Co. KGaA and Omnicell's top-line revenue, earnings per share and valuation.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Omnicell. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Fresenius Medical Care AG & Co. KGaA and Omnicell, as provided by MarketBeat.

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $45.00, indicating a potential upside of 28.42%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, research analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Omnicell.

Risk & Volatility

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats Omnicell on 8 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Catalent and Omnicell's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Catalent and Omnicell's top-line revenue, earnings per share and valuation.

Catalent has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Catalent and Omnicell, as provided by MarketBeat.

Catalent presently has a consensus price target of $121.3750, indicating a potential upside of 4.27%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Catalent's stronger consensus rating and higher possible upside, research analysts clearly believe Catalent is more favorable than Omnicell.

Risk & Volatility

Catalent has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Catalent beats Omnicell on 9 of the 14 factors compared between the two stocks.